Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Brain and Nervous System | Pediatrics
What is the purpose of this trial?
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
- Ages1 year 5 months and younger
- Trial withChildren's Oncology Group (COG)
- Start Date05/27/2022
- End Date06/30/2026
- Last Updated08/04/2022
- Study HIC#1504015715